Aldeyra Therapeutics

Update in progress

ALDX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Aldeyra Therapeutics is a biotechnology company that discovers and develops therapies for immune‑mediated diseases. Its lead candidate, reproxalap, a reactive aldehyde species (RASP) modulator, is in Phase III for dry eye disease and allergic conjunctivitis. ADX‑2191 targets primary vitreoretinal lymphoma and retinitis pigmentosa. ADX‑629 is in Phase II as an oral RASP modulator for COVID‑19, atopic asthma, psoriasis, and alcohol intoxication. Preclinical platforms include ADX‑248 and ADX‑246. Formerly Aldexa Therapeutics; renamed 2014. Founded 2004, based in Lexington, MA.

Company score

Sentiment: 0.09; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive